Evidence map›Paper›PMID 42087463›Full record

ArticleThe Laryngoscope2026

Impact of Co-Morbid Immunocompromise in HPV-Associated Oropharyngeal Squamous Cell Carcinoma.

Maxwell L Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K Evans, Hong-Ho Yang, Christopher Dann, Dipti Sajed, Maie A St John

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maxwell L WengDavid Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID https://orcid.org/0009-0008-5348-6928
Tereza VitkovskaDepartment of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.
Song Hon HwangDepartment of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-0612-3082
Lauran K EvansDepartment of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.
Hong-Ho YangDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.
Christopher DannDepartment of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.
Dipti SajedDepartment of Pathology, David Geffen School of Medicine, Los Angeles, California, USA.
Maie A St JohnDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-7068-9534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo characterize the survival and morbidity associated with immunocompromised status in patients with surgically resected Human Papillomavirus positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).

methodsWe reviewed patients with surgically resected HPV + OPSCC at a tertiary institution between 2000 and 2023. The survival and morbidity associated with an immunocompromised status were assessed with multivariable Cox proportional hazards models controlling for patient, tumor, and treatment characteristics.

resultsAmong 278 patients with HPV+ OPSCC that met inclusion criteria, 14 patients were immunocompromised. Causes of immunocompromise: 4, leukemia or lymphoma; 3, organ transplantation; 3, medically immunosuppressed; 2, HIV; 2, myelodysplastic syndrome and pancytopenia. Adjusting for covariates, the immunocompromised patient group had significantly worse overall survival (64.3% vs. 91.7%; HR 4.12, 95% CI: 1.14-14.90, p < 0.005) compared to the non-compromised group. The immunocompromised patient group did not have a significantly different postoperative length of stay (3.96 vs. 3.5 days; aβ 0.66, 95% CI: -1.30 to 2.64).

conclusionsIn this small, heterogeneous cohort of surgically resected HPV + OPSCC, immunocompromised status was associated with significantly worse overall survival; however, these exploratory findings should be interpreted cautiously. LEVEL OF EVIDENCE: 3:

Indexed as

Carcinoma, Squamous CellHuman Papillomavirus VirusesImmunocompromised HostOropharyngeal NeoplasmsPapillomavirus InfectionsAgedComorbidityFemaleHumansMaleMiddle AgedRetrospective StudiesHIVHPV‐associated oropharyngeal squamous cell carcinomaimmunocompromiseleukemialymphomaorgan transplantationpancytopeniatransoral robotic surgery (TORS)

Identifiers

PMID42087463
PMCPMC13569689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.